Lorenzo Lolli
@lorenzololli.bsky.social
Lead Researcher at Aspire Academy | Research Fellow at Manchester Metropolitan University | Views are my own
Important considerations by @f2harrell.bsky.social in the Evidence for 𝗛𝗼𝗺𝗼geneity of Treatment Effects section in 𝙑𝙞𝙚𝙬𝙥𝙤𝙞𝙣𝙩𝙨 𝙤𝙣 𝙃𝙚𝙩𝙚𝙧𝙤𝙜𝙚𝙣𝙚𝙞𝙩𝙮 𝙤𝙛 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩 𝙀𝙛𝙛𝙚𝙘𝙩 𝙖𝙣𝙙 𝙋𝙧𝙚𝙘𝙞𝙨𝙞𝙤𝙣 𝙈𝙚𝙙𝙞𝙘𝙞𝙣𝙚
Viewpoints on Heterogeneity of Treatment Effect and Precision Medicine – Statistical Thinking
This article provides my reflections after the PCORI/PACE Evidence and the Individual Patient meeting on 2018-05-31. The discussion includes a high-level view of heterogeneity of treatment effect in o...
www.fharrell.com
November 12, 2025 at 7:21 AM
Important considerations by @f2harrell.bsky.social in the Evidence for 𝗛𝗼𝗺𝗼geneity of Treatment Effects section in 𝙑𝙞𝙚𝙬𝙥𝙤𝙞𝙣𝙩𝙨 𝙤𝙣 𝙃𝙚𝙩𝙚𝙧𝙤𝙜𝙚𝙣𝙚𝙞𝙩𝙮 𝙤𝙛 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩 𝙀𝙛𝙛𝙚𝙘𝙩 𝙖𝙣𝙙 𝙋𝙧𝙚𝙘𝙞𝙨𝙞𝙤𝙣 𝙈𝙚𝙙𝙞𝙘𝙞𝙣𝙚
…𝐈𝐟 𝐇𝐓𝐄 𝐞𝐱𝐢𝐬𝐭𝐬, 𝗶𝘁 𝗰𝗮𝗻𝗻𝗼𝘁 𝗮𝗳𝗳𝗲𝗰𝘁 𝗮 𝗽𝘂𝗿𝗲 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 𝗴𝗿𝗼𝘂𝗽 𝗯𝘂𝘁 𝘀𝗵𝗼𝘂𝗹𝗱 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝘁𝗵𝗲 𝘃𝗮𝗿𝗶𝗮𝗻𝗰𝗲 𝗼𝗳 𝗬 𝗶𝗻 𝘁𝗵𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗴𝗿𝗼𝘂𝗽 𝗱𝘂𝗲 𝘁𝗼 𝗵𝗲𝘁𝗲𝗿𝗼𝗴𝗲𝗻𝗲𝗶𝘁𝘆 𝗼𝗳 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗲𝗳𝗳𝗲𝗰𝘁 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝘆𝗽𝗲𝘀 𝗼𝗳 𝘀𝘂𝗯𝗷𝗲𝗰𝘁𝘀.” @f2harrell.bsky.social
Viewpoints on Heterogeneity of Treatment Effect and Precision Medicine – Statistical Thinking
This article provides my reflections after the PCORI/PACE Evidence and the Individual Patient meeting on 2018-05-31. The discussion includes a high-level view of heterogeneity of treatment effect in o...
www.fharrell.com
November 12, 2025 at 7:21 AM
…𝐈𝐟 𝐇𝐓𝐄 𝐞𝐱𝐢𝐬𝐭𝐬, 𝗶𝘁 𝗰𝗮𝗻𝗻𝗼𝘁 𝗮𝗳𝗳𝗲𝗰𝘁 𝗮 𝗽𝘂𝗿𝗲 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 𝗴𝗿𝗼𝘂𝗽 𝗯𝘂𝘁 𝘀𝗵𝗼𝘂𝗹𝗱 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝘁𝗵𝗲 𝘃𝗮𝗿𝗶𝗮𝗻𝗰𝗲 𝗼𝗳 𝗬 𝗶𝗻 𝘁𝗵𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗴𝗿𝗼𝘂𝗽 𝗱𝘂𝗲 𝘁𝗼 𝗵𝗲𝘁𝗲𝗿𝗼𝗴𝗲𝗻𝗲𝗶𝘁𝘆 𝗼𝗳 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗲𝗳𝗳𝗲𝗰𝘁 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝘆𝗽𝗲𝘀 𝗼𝗳 𝘀𝘂𝗯𝗷𝗲𝗰𝘁𝘀.” @f2harrell.bsky.social
Key remarks relevant to avoid unnecessary confusion in clinical trial settings between any endeavor to explore a 𝗺𝗲𝗮𝗻 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗲𝗳𝗳𝗲𝗰𝘁 compared to the more complex examination of 𝙙𝙞𝙨𝙩𝙞𝙣𝙘𝙩 𝙘𝙤𝙢𝙥𝙤𝙣𝙚𝙣𝙩𝙨 𝙤𝙛 𝙫𝙖𝙧𝙞𝙖𝙩𝙞𝙤𝙣 requiring careful research design considerations for (𝒑𝒐𝒕𝒆𝒏𝒕𝒊𝒂𝒍?) 𝙥𝙚𝙧𝙨𝙤𝙣𝙖𝙡𝙞𝙯𝙖𝙩𝙞𝙤𝙣.
Individual Therapy: New Dawn or False Dawn? - Therapeutic Innovation & Regulatory Science
The sequencing of the human genome brings with it the hope that greater understanding of genetic components of disease will allow the more specific targeting of therapies. It has also been suggested t...
link.springer.com
August 20, 2025 at 7:35 AM
Key remarks relevant to avoid unnecessary confusion in clinical trial settings between any endeavor to explore a 𝗺𝗲𝗮𝗻 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗲𝗳𝗳𝗲𝗰𝘁 compared to the more complex examination of 𝙙𝙞𝙨𝙩𝙞𝙣𝙘𝙩 𝙘𝙤𝙢𝙥𝙤𝙣𝙚𝙣𝙩𝙨 𝙤𝙛 𝙫𝙖𝙧𝙞𝙖𝙩𝙞𝙤𝙣 requiring careful research design considerations for (𝒑𝒐𝒕𝒆𝒏𝒕𝒊𝒂𝒍?) 𝙥𝙚𝙧𝙨𝙤𝙣𝙖𝙡𝙞𝙯𝙖𝙩𝙞𝙤𝙣.
“The 𝙛𝙞𝙧𝙨𝙩 is to describe what the effect of treatment was 𝙤𝙫𝙚𝙧 𝙩𝙝𝙚 𝙘𝙤𝙪𝙧𝙨𝙚 𝙤𝙛 𝙖 𝙨𝙩𝙪𝙙𝙮.
The 𝒔𝒆𝒄𝒐𝒏𝒅 is to describe what effect the treatment had attained 𝒃𝒚 𝒕𝒉𝒆 𝒆𝒏𝒅 𝒐𝒇 𝒕𝒉𝒆 𝒔𝒕𝒖𝒅𝒚.”
The 𝒔𝒆𝒄𝒐𝒏𝒅 is to describe what effect the treatment had attained 𝒃𝒚 𝒕𝒉𝒆 𝒆𝒏𝒅 𝒐𝒇 𝒕𝒉𝒆 𝒔𝒕𝒖𝒅𝒚.”
Repeated measures in clinical trials: simple strategies for analysis using summary measures
The summary measures approach to analysing repeated measures is described. The circumstances under which it can be advantageous to use such measures are considered. Strategies for baseline adjustment...
onlinelibrary.wiley.com
August 20, 2025 at 7:35 AM
“The 𝙛𝙞𝙧𝙨𝙩 is to describe what the effect of treatment was 𝙤𝙫𝙚𝙧 𝙩𝙝𝙚 𝙘𝙤𝙪𝙧𝙨𝙚 𝙤𝙛 𝙖 𝙨𝙩𝙪𝙙𝙮.
The 𝒔𝒆𝒄𝒐𝒏𝒅 is to describe what effect the treatment had attained 𝒃𝒚 𝒕𝒉𝒆 𝒆𝒏𝒅 𝒐𝒇 𝒕𝒉𝒆 𝒔𝒕𝒖𝒅𝒚.”
The 𝒔𝒆𝒄𝒐𝒏𝒅 is to describe what effect the treatment had attained 𝒃𝒚 𝒕𝒉𝒆 𝒆𝒏𝒅 𝒐𝒇 𝒕𝒉𝒆 𝒔𝒕𝒖𝒅𝒚.”
“Neither 𝙢𝙚𝙖𝙣𝙨 nor 𝒔𝒍𝒐𝒑𝒆𝒔 are likely to describe perfectly the way in which the effect of treatment 𝙫𝙖𝙧𝙞𝙚𝙨 with time.
In this connection it is useful to distinguish two common purposes of summaries.”
In this connection it is useful to distinguish two common purposes of summaries.”
August 20, 2025 at 7:35 AM
“Neither 𝙢𝙚𝙖𝙣𝙨 nor 𝒔𝒍𝒐𝒑𝒆𝒔 are likely to describe perfectly the way in which the effect of treatment 𝙫𝙖𝙧𝙞𝙚𝙨 with time.
In this connection it is useful to distinguish two common purposes of summaries.”
In this connection it is useful to distinguish two common purposes of summaries.”